{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T22:32:38Z","timestamp":1793140358608,"version":"4.5.0"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.eclinm.2026.104174","type":"journal-article","created":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T15:04:19Z","timestamp":1788188659000},"page":"104174","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Second ipsilateral locoregional recurrence in patients with hormone receptor-positive, HER2-negative breast cancer: a cohort study"],"prefix":"10.1016","volume":"99","author":[{"given":"Monica","family":"Milano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1150-0345","authenticated-orcid":false,"given":"Carmine","family":"Valenza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Bianco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Manacorda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Cavallone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Letizia","family":"Matera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-4892-7775","authenticated-orcid":false,"given":"Renato Maria","family":"Marsicano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Battaiotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5559-7279","authenticated-orcid":false,"given":"Pier Paolo Maria","family":"Berton Giachetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-3587-1408","authenticated-orcid":false,"given":"Edoardo","family":"Giordano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian David","family":"Etessami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"Trapani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Schena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Sangalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Kahler Ribeiro Fontana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1348-4548","authenticated-orcid":false,"given":"Sara","family":"Gandini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Veronesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viviana","family":"Galimberti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Colleoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1781-2518","authenticated-orcid":false,"given":"Giuseppe","family":"Curigliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3371-3878","authenticated-orcid":false,"given":"Elisabetta","family":"Munzone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eclinm.2026.104174_bib1","article-title":"Cancer statistics, 2026","volume":"76","author":"Siegel","year":"2026","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.eclinm.2026.104174_bib2","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/S0140-6736(24)01745-8","article-title":"Reductions in recurrence in women with early breast cancer entering clinical trials between 1990 and 2009: a pooled analysis of 155 746 women in 151 trials","volume":"404","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.eclinm.2026.104174_bib3","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1001\/jama.1994.03510440047031","article-title":"Impact of follow-up testing on survival and health-related quality of life in breast cancer patients","volume":"271","author":"Ghezzi","year":"1994","journal-title":"JAMA"},{"key":"10.1016\/j.eclinm.2026.104174_bib4","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1001\/jama.1994.03510440053032","article-title":"Intensive diagnostic follow-up after treatment of primary breast cancer. A randomized trial. National Research Council Project on Breast Cancer follow-up","volume":"271","author":"Rosselli Del Turco","year":"1994","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.eclinm.2026.104174_bib5","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1200\/JCO.19.02806","article-title":"Multidisciplinary management of locoregional recurrent breast cancer","volume":"38","author":"Buchholz","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eclinm.2026.104174_bib6","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.breast.2018.03.011","article-title":"Incidence of isolated local breast cancer recurrence and contralateral breast cancer: a systematic review","volume":"39","author":"Spronk","year":"2018","journal-title":"Breast"},{"key":"10.1016\/j.eclinm.2026.104174_bib7","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1093\/annonc\/mdg347","article-title":"Adjuvant therapy after excision and radiation of isolated postmastectomy locoregional breast cancer recurrence: definitive results of a phase III randomized trial (SAKK 23\/82) comparing tamoxifen with observation","volume":"14","author":"Waeber","year":"2003","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eclinm.2026.104174_bib8","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1016\/j.annonc.2025.09.007","article-title":"Tailoring treatment to cancer risk and patient preference: the 2025 St Gallen International Breast Cancer Consensus Statement on individualizing therapy for patients with early breast cancer","volume":"36","author":"Burstein","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eclinm.2026.104174_bib9","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1245\/s10434-016-5571-y","article-title":"Poor prognosis after second locoregional recurrences in the CALOR trial","volume":"24","author":"Wapnir","year":"2017","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.eclinm.2026.104174_bib10","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1056\/NEJMoa1600249","article-title":"Breast-cancer tumor size, overdiagnosis, and mammography screening effectiveness","volume":"375","author":"Welch","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eclinm.2026.104174_bib11","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1056\/NEJMoa1701830","article-title":"20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years","volume":"377","author":"Pan","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eclinm.2026.104174_bib12","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.annonc.2023.11.016","article-title":"Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"35","author":"Loibl","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eclinm.2026.104174_bib13","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1097\/SLA.0b013e318208fc2a","article-title":"Classification of ipsilateral breast tumor recurrences after breast conservation therapy can predict patient prognosis and facilitate treatment planning","volume":"253","author":"Yi","year":"2011","journal-title":"Ann Surg"},{"key":"10.1016\/j.eclinm.2026.104174_bib14","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/S0959-8049(98)00301-3","article-title":"Prognosis after treatment for loco-regional recurrence after mastectomy or breast conserving therapy in two randomised trials (EORTC 10801 and DBCG-82TM)","volume":"35","author":"van Tienhoven","year":"1999","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.eclinm.2026.104174_bib15","doi-asserted-by":"crossref","first-page":"3364","DOI":"10.1245\/s10434-025-17514-3","article-title":"Outcomes of second breast-conserving surgery without reirradiation for breast tumor recurrence","volume":"33","author":"Gaillard","year":"2026","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.eclinm.2026.104174_bib16","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/j.ejso.2019.02.008","article-title":"Repeat breast-conserving therapy for ipsilateral breast cancer recurrence: a systematic review","volume":"45","author":"Walstra","year":"2019","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.eclinm.2026.104174_bib17","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1200\/JCO.2017.76.5719","article-title":"Efficacy of chemotherapy for ER-negative and ER-positive isolated locoregional recurrence of breast cancer: final analysis of the CALOR trial","volume":"36","author":"Wapnir","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eclinm.2026.104174_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.105889","article-title":"Association between adjuvant chemotherapy and outcomes in resected locoregional recurrence of hormone receptor-positive HER2-negative breast cancer: a multi-institutional retrospective study","volume":"10","author":"Ozaki","year":"2025","journal-title":"ESMO Open"},{"key":"10.1016\/j.eclinm.2026.104174_bib19","doi-asserted-by":"crossref","first-page":"4594","DOI":"10.1200\/JCO.2010.28.8415","article-title":"Results of the CONFIRM Phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor\u2013positive advanced breast cancer","volume":"28","author":"Di Leo","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eclinm.2026.104174_bib20","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1200\/JCO.2007.13.5822","article-title":"Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor\u2013positive, advanced breast cancer: results from EFECT","volume":"26","author":"Chia","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eclinm.2026.104174_bib21","doi-asserted-by":"crossref","first-page":"GS1-10-10","DOI":"10.1158\/1557-3265.SABCS25-GS1-10","article-title":"Abstract GS1-10: giredestrant vs standard-of-care endocrine therapy as adjuvant treatment for patients with estrogen receptor-positive, HER2-negative early breast cancer: results from the global Phase III lidERA breast cancer trial","volume":"32","author":"Bardia","year":"2026","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eclinm.2026.104174_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2026.103093","article-title":"Comparative efficacy and safety of novel oral selective estrogen receptor degraders in ER+\/HER2\u2013 advanced breast cancer: an updated systematic review and meta-analysis of randomized controlled trials","volume":"143","author":"Kirmani","year":"2026","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.eclinm.2026.104174_bib23","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.annonc.2025.10.005","article-title":"Overall survival with abemaciclib in early breast cancer","volume":"37","author":"Johnston","year":"2026","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eclinm.2026.104174_bib24","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1056\/NEJMoa2305488","article-title":"Ribociclib plus endocrine therapy in early breast cancer","volume":"390","author":"Slamon","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eclinm.2026.104174_bib25","doi-asserted-by":"crossref","first-page":"PS5","DOI":"10.1158\/1557-3265.SABCS25-PS5-07-24","article-title":"Abstract PS5-07-24: a randomized phase III trial for evaluating the efficacy of adjuvant abemaciclib in patients with locoregional recurrence of hormone receptor-positive, HER2-negative breast cancer: JCOG2313 (AURA study)","volume":"32","author":"Tokuda","year":"2026","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eclinm.2026.104174_bib26","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.SABCS20-OT-26-02","volume":"81","author":"Munzone","year":"2021","journal-title":"Cancer Res"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S258953702600427X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S258953702600427X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T21:35:17Z","timestamp":1793136917000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S258953702600427X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":26,"alternative-id":["S258953702600427X"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2026.104174","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Second ipsilateral locoregional recurrence in patients with hormone receptor-positive, HER2-negative breast cancer: a cohort study","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2026.104174","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104174"}}